This is the first study to show targeting of CSPG4 on tumor cells after decitabine-mediated upregulation raising the hypothesis for CSPG4 as an inducible secondary antigen on solid tumors with special emphasis on ovarian cancer. Here, CSPG4 is linked to ovarian cancer.